Astellas submitted to the EMA prostate cancer drugs enzalutamide marketing authorization application
Astellas Pharma (Astellas) announced that it has submitted to EMA enzalutamide (MDV3100) Marketing Authorization Application (MAA), for the treatment received docetaxel chemotherapy for castration-resistant prostate cancer metastasis.
Enzalutamide is a drug once a day, for the androgen receptor signal transduction inhibitors. In May this year, Astellas partner Medivation Company has submitted enzalutamide FDA New Drug Application (NDA), while the company asked the FDA to give the drug a priority review.
Astellas submitted to the EMA prostate cancer drugs enzalutamide marketing authorization application
ReplyDeleteAstellas Pharma (Astellas) announced that it has submitted to EMA enzalutamide (MDV3100) Marketing Authorization Application (MAA), for the treatment received docetaxel chemotherapy for castration-resistant prostate cancer metastasis.
Enzalutamide is a drug once a day, for the androgen receptor signal transduction inhibitors. In May this year, Astellas partner Medivation Company has submitted enzalutamide FDA New Drug Application (NDA), while the company asked the FDA to give the drug a priority review.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
ENMD-2076 TARTARIC ACID
ENMD-2076
SNS-314
CCT129202
Hesperadin
PF-03814735
AT9283
GSK-1070916
MK-5108
Aurora A inhibitor I